Global Anticoccidial Drugs Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Drug Type (Antibiotic Anticoccidials, Ionophore Anticoccidials & Chemical derivative Anticoccidials), Animal Type and Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa) - Industry Forecast (2024 to 2029)

Updated On: January, 2024
ID: 1
Pages: 175

Global Anticoccidial Drugs Market Size (2024 to 2029)

The global anticoccidial drugs market is expected to have a 3.61% CAGR from 2024 to 2029 and the global market size is anticipated to be worth USD 1752 Mn by 2029 from USD 1468 Mn in 2024.

Anticoccidial drugs are used to prevent and treat coccidiosis in animals. When animals are diagnosed with coccidiosis, they suffer from diarrhea, weight loss, and reduced growth and productivity. Coccidiosis can also result in death in some cases. Coccidiosis majorly impacts the intestines of animals. This parasitic disease is infectious. To treat coccidiosis, anticoccidial drugs are used in the treatment procedures to remove the parasites. Anticoccidial drugs are of two types, ionophores and chemical anticoccidials. Monensin and salinomycin are ionophores, and sulfonamides and nitroimidazoles are chemical anticoccidials. As said earlier, these drugs are primarily used to control the spread of coccidiosis; however, the consumption of the drugs must be according to the saying of veterinarians, and overuse of these drugs could result in other animal problems.


The growing prevalence of coccidiosis and the rising focus on veterinary healthcare are primarily accelerating the growth of the global anticoccidial drugs market.

Anticoccidial drugs are the agents used to treat, prevent, and control coccidial infections. However, there is a risk of increased coccidiosis due to environmental factors and other issues related to hygienic measures. Hence, there is an alarming demand for newer anticoccidial drugs in the drug market. Increasing the need to prevent the spread of diseases in animals with effective medication and the rise in the consumption rate of meat and poultry products are further propelling the growth of the global anticoccidial drugs market.

The growing number of veterinary hospitals, the rise in demand to improve the quality of drugs with different techniques, the growing disposable income in urban areas, and people's concern for maintaining a healthy diet are further promoting the growth of the global anticoccidial drugs market. According to the data published by the American Veterinary Medical Association (AVMA), an estimated 20,000 veterinary clinics, hospitals, and 90,000 veterinary practitioners were there in the United States in 2021.

The growing support from the government through investments, the rising demand to increase the production rate of drugs with high quality, and increasing concern towards animals' health conditions further accelerate market growth. For instance, the United States Department of Agriculture (USDA) invested an amount of USD 19 million in conducting R&D for animal health and animal diseases to prevent, control, and treat various diseases in livestock and poultry and to innovate new veterinary medical equipment, diagnostic tools, and treatment procedures via NIFA in 2019. Likewise, the Australian government announced an investment of USD 100 million for veterinary healthcare, primarily to conduct R&D to develop advanced medical devices, drugs, and treatment procedures for various animal diseases in 2020.

Furthermore, the adoption of the latest technology, the launch of valuable products, and the rising number of infectious diseases among animals and birds are expected to fuel the growth opportunities for the global anticoccidial drugs market during the forecast period.


The growing number of regulatory restrictions and stringency is majorly hindering the global anticoccidial drugs market growth.

However, the need for more skilled persons in manufacturing appropriate drugs with correct dosage forms slowly restricts the global anticoccidial drug market growth. In addition, the availability of other drugs at a lower cost and fluctuations in the prices of final products due to less availability of raw materials are expected to limit the growth of the global anticoccidial drugs market.

Impact Of COVID-19 On the Global Anticoccidial Drugs Market

The disease has spread to almost every country globally since the COVID-19 virus outbreak in December 2019, prompting the World Health Organization to declare it a public health emergency. Coccidiosis is a viral disease caused by a single-cell parasite that can only be seen under a microscope. It affects the intestinal tracts of animals. Weight loss, moderate sporadic to extreme diarrhea, diarrhea containing blood or mucus, dehydration, and decreased breeding are all signs of coccidiosis, one of the most common parasitic diseases in domesticated animals. Growing clinical trials in developing medicines or vaccines for animals to prevent infections propels this market's growth rate to new heights. Anticoccidial drugs are drug preparations used to treat coccidiosis in animals. These are given to animals and birds to stop coccidia from reproducing and destroying protozoa in the intestine. In some countries, the transmission of coronavirus from humans to animals boosts the market's growth rate during these pandemic times. In addition, key strategies and increasing awareness of social distancing and wearing masks among market players are expected to boost demand for anticoccidial drugs during the forecast period.




Market Size Available

2023 to 2029

Base Year


Forecast Period

2024 to 2029

Segments Analysed

By Drug Type, Animal type, and region

Various Analyses Covered

Global, Regional, & Country Level Analysis; Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape; Analyst Overview of Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Key Market Players

Bayer Health Care, Zoetis, Elanco, Merial, Merck Animal Healthcare, Ceva Santé Animale, Virbac, Boehringer Ingelheim Animal Health, Novartis Animal Healthcare, and Smartvet Inc.



Global Anticoccidial Drugs Market Analysis By Drug Type

Based on drug type, the ionophore anticoccidials segment dominated the market with 42.9% of the global market share in 2023. The growth of the ionophore segment is majorly attributed to the growing awareness regarding the advantages of ionophores, such as improved efficacy, faster action, and a lower risk of drug resistance developing among veterinary practitioners. In addition, the growing R&D activities around ionophores to bring innovative and effective drugs to the market further promote the segment's growth rate. Furthermore, ionophores are safe for animals as they contain low toxicity levels, due to which the adoption of ionophores is growing and resulting in segmental growth.

The antibiotic segment is another key segment and is expected to grow at the fastest CAGR of 8.04% during the forecast period. The rise in the scale of research institutes to introduce certain types of drugs at high quality with the latest technology boosts segmental growth. Also, the growing economy in almost every region magnifies the segment's growth rate. 

Global Anticoccidial Drugs Market Analysis By Animal Type

Based on animal type, the poultry animal segment led the anticoccidial drugs market with 41.8% of the global market share in 2023 and the domination of the segment is likely to continue during the forecast period. The growing adoption of anticoccidial drugs primarily drives the segment's growth by poultry producers to improve the productivity and overall health of the birds. In addition, the emergence of the latest technological developments and the growing incidence of coccidiosis, especially in food-producing animals, are fuelling the segment's growth rate.

On the other hand, the companion animal segment is anticipated to witness a promising CAGR during the forecast period. Factors such as increasing pet ownership worldwide, rising awareness regarding veterinary healthcare, and the availability of anticoccidial drugs in several countries are promoting segmental growth. As a result, the adoption of companion animals such as cats and dogs is growing significantly worldwide. In addition, the growing incidence of coccidiosis among companion animals accelerates the segment's growth.


Regionally, North America was the most dominating region in the global market and accounted for 36.3% of the global market share in 2023. The adoption of advanced manufacturing drug techniques majorly drives this regional market. In addition, launching innovative medicines that favor producing the most top-quality products significantly influences the global anticoccidial drugs market. The adoption of companion animals is increasing in North American countries, which is expected to contribute to the growth of the North American market. For instance, dogs are widely adopted in the U.S., followed by cats. According to studies, 60 million households have dogs as pets, and 47 million have cats as their pets in the United States. The presence of well-organized animal healthcare systems in the North American region favors the anticoccidial drugs market in this region. The increasing accessibility of anticoccidial drugs to pet owners via veterinary hospitals and online pharmacies is anticipated to favor regional market growth.

Asia-Pacific is forecasted to be growing at a CAGR of 4.3% during the forecast period. The Asia Pacific market accounted for the second largest global market share in 2023 owing to the growing pet population, increasing demand for poultry products, and increasing support and funding from the APAC countries. In addition, the growth rate of the APAC market is also fuelled by the increasing scale of the regional pharmaceutical industries.

Europe is predicted to grow at a promising CAGR during the forecast period due to the growing meat consumption rate. Furthermore, the presence of a sophisticated pet care industry in the European region is anticipated to boost the growth rate of the European market. In addition, factors such as the growing usage of anticoccidial drugs for companion animals and poultry animals in European countries and the growing availability of anticoccidial drugs via various channels are favoring the growth of the European market. As a result, the U.K. market is estimated to account for most of the share in the European market during the forecast period.

Latin America is projected to grow steadily during the forecast period. Brazil, followed by Mexico, led the anticoccidial drugs market in Latin America in 2023.

The Middle East and Africa market is projected to have a prominent growth rate in the coming years. The usage of anticoccidial drugs is growing substantially in the Middle East and African countries owing to the growing MEA poultry industry and increasing incidence of coccidiosis among birds. In addition, the rising consumption levels of meat and poultry products are expected to fuel the need for anticoccidial drugs in this region during the forecast period.


Noteworthy companies in the global anticoccidial drugs market profiled in this report are Bayer Health care, Zoetis, Elanco, Merial, Merck Animal Healthcare, Ceva Santé Animale, Virbac, Boehringer Ingelheim Animal Health, Novartis Animal Healthcare, and Smartvet Inc. The global anticoccidial drugs market is highly competitive, and major players have adopted product development strategies, mergers, acquisitions, and partnerships to maximize their market share.


  • In April 2022, Amlan International, a U.S.-based company operating in veterinary healthcare, announced natural alternatives to anticoccidial drugs.
  • In May 2020, Zoetis showed suckling calves with significant weight gain from implants. It is a considerable increase in weaning weight.
  • In September 2019, Virbac launched Multimin, which is used for cattle.
  • In October 2019, Ceva Sante Animale agreed with ProBioGen, the manufacturer, to represent a transformation of poultry vaccines with the help of ProBioGen's proprietary AGE1.CR technology. AGE1 is a preserved cell line that is obtained from the duck. This cell line is created as a platform to restore chicken cells to manufacture vaccines related to poultry. In addition, Ceva and ProBioGen have a long track in introducing new veterinary vaccines through additional research and development programs.


This research report on the global anticoccidial drugs market has been segmented and sub-segmented based on the drug type, animal type, and region.

By Drug Type

  • Antibiotic
  • Ionophore
  • Chemical Derivative

By Animal Type

  • Poultry
  • Swine
  • Fish
  • Cattle
  • Companion Animal

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Please wait. . . . Your request is being processed

Frequently Asked Questions

What is the future expected growth rate for global anticoccidial drugs market?

Between 2023 to 2028, the global anticoccidial drugs market is forecasted to grow at a CAGR of 3.61%.

Which anticoccidial drug type is expected to grow well in the future?

Based on the various drug types, the Ionophore anticoccidial drugs type is expected to dominate the market and account for the leading share in the global market during the forecast period

Which region is expected to register fastest growth in the worldwide anticoccidial drugs market?

North American market led the global market in 2022. However, during the forecast period, the North American region is expected to grow the fastest.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample